Retatrutide is not approved by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) and remains under clinical investigation
Romanowska, M
This helps improve uneven skin tone, sun-related pigmentation, and dark patches
Preclinical research suggests that GLP-1 receptor activation may strengthen tight junctions between intestinal epithelial cells, reducing the translocation of bacterial products (like lipopolysaccharide) that trigger systemic immune activation
Zhou Y, Suo W, Zhang X, Liang J, Zhao W, Wang Y, Li H, Ni Q
Product labeling also includes contraindication language for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2